Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Total Liabilities (2016 - 2025)

Ani Pharmaceuticals' Total Liabilities history spans 16 years, with the latest figure at $899.7 million for Q4 2025.

  • For Q4 2025, Total Liabilities rose 5.2% year-over-year to $899.7 million; the TTM value through Dec 2025 reached $899.7 million, up 5.2%, while the annual FY2025 figure was $899.7 million, 5.2% up from the prior year.
  • Total Liabilities for Q4 2025 was $899.7 million at Ani Pharmaceuticals, roughly flat from $902.3 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $902.3 million in Q3 2025 and bottomed at $260.1 million in Q1 2021.
  • The 5-year median for Total Liabilities is $430.5 million (2023), against an average of $536.6 million.
  • The largest annual shift saw Total Liabilities fell 7.45% in 2021 before it soared 100.25% in 2025.
  • A 5-year view of Total Liabilities shows it stood at $412.9 million in 2021, then increased by 2.1% to $421.5 million in 2022, then rose by 6.0% to $446.8 million in 2023, then skyrocketed by 91.39% to $855.2 million in 2024, then rose by 5.2% to $899.7 million in 2025.
  • Per Business Quant, the three most recent readings for ANIP's Total Liabilities are $899.7 million (Q4 2025), $902.3 million (Q3 2025), and $881.4 million (Q2 2025).